Dyne Therapeutics plans to file for approval for next-generation Duchenne drug. The medicine could be a more effective version of controversial Sarepta
Happy Monday morning! Should be a busy one, with weekend ASH stock trading + $KYMR$DYN$GPCR$WVE data readouts.
And, of course, everyone will be buying more $ABVX